Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

GP's study predicts contract will hit morale

NICE is in discussions with the Association of the British Pharmaceutical Industry over ways of improving implementation of its guidance.

The move follows the decision by the Scottish Intercollegiate Guidelines Network to formally collaborate with the ABPI on the implementation of its osteoporosis advice.

The GPC condemned the association, saying 'any formal link could be misconstrued' and expressing concern at the growing links between guidance committees and the pharmaceutical industry.

SIGN's collaboration with the ABPI is the first of its kind and involves joint websites, conferences and workshops.

NICE has not yet discussed 'guideline-specific' issues and admitted firms would work harder to implement guidance when their own products were recommended. But it plans to consider applications to collaborate on implementation 'on a case-by-case basis'.

Dr Chaand Nagpaul, GPC prescribing sub-committee member, called such collaborations 'inappropriate' and said: 'It is important for SIGN and NICE to be seen to be truly independent of industry.'

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say